Compare Moderna, Inc. (MRNA) vs United Airlines Holdings Inc (UAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs United Airlines Holdings Inc — how do they compare? Moderna, Inc. trades at $207.77 (market cap $78.65B), while United Airlines Holdings Inc trades at $105.51 (market cap $34.87B). The key difference: Moderna, Inc. is far larger — about 2.3× United Airlines Holdings Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, United Airlines Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and United Airlines Holdings Inc for 46 Days on average.
| MRNA | UAL | |
|---|---|---|
Market Cap | $78.65B | $34.87B |
Volume | 37,373,437 | 6,329,678 |
Sector | Health | Industrials |
52-Week High | $203.46 | $136.11 |
52-Week Low | $22.36 | $85.21 |
Typical Hold Time | 59 Days | 46 Days |
Enterprise Value | $74.80B | $51.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.
While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.
United Airlines (UAL) trades at $110.17, down 1.53% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 10.06, net income margin of 5.56%, and three consecutive quarterly EPS beats. Recent news highlights aggressive customer acquisition tactics targeting Delta's elite travelers with status-match offers and Starlink WiFi advantages.
Outlook remains positive given analyst consensus of $158.10 price target and 66% buy ratings, but risks include rising fuel costs, labor expenses, and competitive pressures. Earnings growth and market share gains are key catalysts, though near-term volatility persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About United Airlines Holdings Inc
United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.
Read more on UAL →
